Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

1.76 EUR+1.74 %9.11. klo 18.29
5,682 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+1.74 %
+22.80 %
+6.55 %
+13.88 %
-53.42 %
-57.17 %
-33.74 %
-82.30 %
-61.66 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
37.75M EUR
Turnover
318.95K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
09.11.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
A contract liability is billed or paid prior to performance, and the growth in receivables in Q3 suggests that a large portion is billed and not yet in cash; it is recognized as revenue according to the performance obligation – partly as recurring (Lumo software, maintenance), partly...
10 hours ago
by Juha Kinnunen
26
Yeah, and it was also stated on two separate occasions that the majority of the growth came from Aurora AEYE after some circumlocution. Of course, there’s other stuff in there too, but it would be total hair-splitting to try to estimate that, say, 25–50 TEUR is Lumo software stream...
10 hours ago
by Juha Kinnunen
24
Your numbers are correct. The Devices segment’s gross margin was 68.4% in Q3, and excluding the 196 kEUR customs refund, it was 61.9%, compared to around 62.6% in Q1. However, in my opinion, you can’t conclude much from the percentage alone, because the Q3 mix was exceptional. Out...
10 hours ago
by Juha Kinnunen
22
You can expect one, but as a rule, we don’t disclose publications in advance.
11 hours ago
by Juha Kinnunen
11
The question regarding the potential growth in RR revenue kept bothering yours truly, so here is an assessment of what lies ahead based on the Q3/2026 financial statements. Contract liabilities (advances received and deferred revenue, a beloved child has many names) grew +72% year...
11 hours ago
by Dr.Feelgood
8
I actually checked this, and indeed, US tariffs did reduce profitability in H2 2025—Optomed itself explicitly states in its annual report: “US import tariffs began to affect gross margins in the second half of the year.” Before the tariffs impacted profitability, the Devices segment...
8 hours ago
by Choyoba_Capital
5
Could we get a clear / specific answer to this, perhaps in connection with the next interview? Because based on my interpretation, and knowing Himberg’s evasive answering style, he could very well have just meant that revenue has grown every quarter. In my opinion, this would be ...
10 hours ago
by Choyoba_Capital
4
Read more on our forum
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.2.
2027

Annual report '26

4.5.
2027

Interim report Q1'27

11.5.
2027

General meeting '27

Press release09.11.2026 klo 15.03

Redeye: Optomed (Q3 Review): Strong cost control, but the topline has yet to convince

Optomed
Optomed Q3'26: Earnings improved and costs are decreasing36:52
Video06.11.2026 klo 16.59
by Juha Kinnunen

Optomed Q3'26: Earnings improved and costs are decreasing

Optomed's earnings developed better than expected in the quarter, as costs decreased and Optomed focused even more closely on the growth potential of better profitability. CEO Juho Himberg is interviewed by analyst Juha Kinnunen.

Optomed
Regulatory press release06.11.2026 klo 09.00

Optomed Plc: Interim report January - September 2026

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release07.10.2026 klo 14.00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release28.09.2026 klo 16.17

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026 klo 16.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026 klo 16.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026 klo 16.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026 klo 16.12

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026 klo 16.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026 klo 16.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026 klo 16.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026 klo 16.07

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026 klo 16.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026 klo 16.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026 klo 16.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026 klo 16.01

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026 klo 16.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026 klo 16.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026 klo 16.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed